Contact- and agonist-regulated microvesiculation of human platelets

Summary

After exposure to an agonist, platelets are activated and become aggregated. They also shed membrane microparticles that participate in the pathogenesis of thrombosis, hyper-coagulation and inflammation. However, microvesiculation can potentially disrupt the integrity of platelet aggregation by shedding the membrane receptors and phosphatidylserine critical for forming and stabilising a platelet clot. We tested the hypothesis that adhesion and microvesiculation are functions of different subsets of platelets at the time of haemostasis by real-time monitoring of agonist-induced morphological changes and microvesiculation of human platelets. We identified two types of platelets that are adherent to fibrinogen: a high density bubble shape (HDBS) and low-density spread shape (LDSS). Adenosine diphosphate (ADP) predominantly induced HDBS platelets to vesiculate, whereas LDSS platelets were highly resistant to such vesiculation. Thrombin-receptor activating peptide (TRAP) stabilised platelets against microvesiculation by promoting a rapid HDBS-to-LDSS morphological transition. These activities of ADP and TRAP were reversed for platelets in suspension, independent of an engagement integrin αIIbβ 3. As the result of membrane contact, LDSS platelets inhibited the microvesiculation of HDBS platelets in response to ADP. Aspirin and clopidogrel inhibited ADP-induced microvesiculation through different mechanisms. These results suggest that platelet aggregation and microvesiculation occur in different subsets of platelets and are differently regulated by agonists, platelet-platelets and platelet-fibrinogen interactions.

Keywords

Platelets - microvesiculation - contact inhibition - anti-platelet drugs

• References

• 1 Zwaal RF. et al. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62: 971-988.
• 2 Sinauridze EI. et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 3 Connor DE. et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010; 103: 1044-1052.
• 4 Pasquet JM. et al. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Eur J Biochem 1996; 239: 647-654.
• 5 Italiano Jr. JE. et al. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010; 17: 578-584.
• 6 Moroi M. et al. Involvement of activated integrin alpha2beta1 in the firm adhesion of platelets onto a surface of immobilized collagen under flow conditions. Thromb Haemost 2000; 83: 769-776.
• 7 Ratajczak J. et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-1495.
• 8 van der Zee PM. et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-664.
• 9 Baj-Krzyworzeka M. et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chaemotaxis of hematopoietic cells. Exp Hematol 2002; 30: 450-459.
• 10 Henseleit U. et al. Effects of divalent cations on lipid flip-flop in the human erythrocyte membrane. Biochim Biophys Acta 1990; 1029: 127-135.
• 11 Shcherbina A. et al. Role of caspase in a subset of human platelet activation responses. Blood 1999; 93: 4222-4231.
• 12 Dale GL, Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost 2006; 04: 2664-2669.
• 13 Schoenwaelder SM. et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.
• 14 Heemskerk JW. et al. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
• 15 Bevers EM. et al. Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity. Biochemistry 1989; 28: 2382-2387.
• 16 Bird GS. et al. Mechanisms of phospholipase C-regulated calcium entry. Curr Mol Med 2004; 04: 291-301.
• 17 Fox JE. et al. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-13295.
• 18 Zhang H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943-951.
• 19 Mason KD. et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
• 20 Liu X. et al. High-resolution morphological identification and characterisation of living neuroblastoma SK-N-SH cells by hopping probe ion conductance microscopy. Brain Res 2011; 1386: 35-40.
• 21 Yang X. et al. Investigation of morphological and functional changes during neuronal differentiation of PC12 cells by combined Hopping Probe Ion Conductance Microscopy and patch-clamp technique. Ultramicroscopy 2011; 111: 1417-1422.
• 22 Novak P. et al. Nanoscale live-cell imaging using hopping probe ion conductance microscopy. Nat Methods 2009; 06: 279-281.
• 23 Shah MD. et al. Flow cytometric measurement of microparticles: pitfalls and protocol modifications. Platelets 2008; 19: 365-372.
• 24 Berckmans RJ. et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
• 25 Yan R. et al. Role of cAMP-dependent protein kinase in the regulation of platelet procoagulant activity. Arch Biochem Biophys 2009; 485: 41-48.
• 26 Noe L. et al. Regulators of platelet cAMP levels: clinical and therapeutic implications. Curr Med Chem 2010; 17: 2897-2905.
• 27 Vlahos CJ. et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
• 28 Gilio K. et al. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signalling and thrombus formation. J Biol Chem 2009; 284: 33750-33762.
• 29 Flaumenhaft R. et al. Platelet- and megakaryocyte-derived microparticles. Semin Thromb Haemost 2010; 36: 881-887.
• 30 Leytin V. et al. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 04: 2656-2663.
• 31 Lin KH. et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents. Platelets 2009; 20: 575-581.
• 32 Cauwenberghs S. et al. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilisation of actin cytoskeleton. FEBS Lett 2009; 580: 5313-5320.
• 33 Heemskerk JW. et al. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca²⁺ responses. Blood 1997; 90: 2615-2625.
• 34 Razmara M. et al. Glycoprotein IIb/IIIa blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity. Cell Mol Life Sci 2007; 64: 999-1008.
• 35 Behan MW. et al. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005; 16: 73-80.